Tahikinin (Serbo-Croatian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tahikinin" in Serbo-Croatian language version.

refsWebsite

Global rank Serbo-Croatian rank

20nih.gov

4^th place

3^rd place

13doi.org

2^nd place

4web.archive.org

1^st place

4bentham-direct.org

low place

5,831^st place

3archive.org

6^th place

5^th place

1jneurosci.org

low place

6,048^th place

1elsevier.com

610^th place

525^th place

archive.org

Maggio JE (1988). „Tachykinins”. Annu. Rev. Neurosci. 11: 13–28. DOI:10.1146/annurev.ne.11.030188.000305. PMID 3284438.
Salomé N, Stemmelin J, Cohen C, Griebel G (April 2006). „Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils”. Pharmacol. Biochem. Behav. 83 (4): 533–9. DOI:10.1016/j.pbb.2006.03.013. PMID 16624395.
Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G (March 2008). „Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models”. Pharmacol. Biochem. Behav. 89 (1): 36–45. DOI:10.1016/j.pbb.2007.10.020. PMID 18045668.

bentham-direct.org

Chahl LA (August 2006). „Tachykinins and neuropsychiatric disorders”. Curr Drug Targets 7 (8): 993–1003. DOI:10.2174/138945006778019309. PMID 16918327. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.
Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer A (August 2006). „Tachykinins in the respiratory tract”. Curr Drug Targets 7 (8): 1005–10. DOI:10.2174/138945006778019318. PMID 16918328. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.
Improta G, Broccardo M (August 2006). „Tachykinins: role in human gastrointestinal tract physiology and pathology”. Curr Drug Targets 7 (8): 1021–9. DOI:10.2174/138945006778019354. PMID 16918330. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.
Quartara L, Altamura M (August 2006). „Tachykinin receptors antagonists: from research to clinic”. Curr Drug Targets 7 (8): 975–92. DOI:10.2174/138945006778019381. PMID 16918326. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.

doi.org

dx.doi.org

Maggio JE (1988). „Tachykinins”. Annu. Rev. Neurosci. 11: 13–28. DOI:10.1146/annurev.ne.11.030188.000305. PMID 3284438.
Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C (August 1993). „Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior”. Physiol. Behav. 54 (2): 249–58. DOI:10.1016/0031-9384(93)90107-Q. PMID 7690487.
Duffy RA (May 2004). „Potential therapeutic targets for neurokinin-1 receptor antagonists”. Expert Opin Emerg Drugs 9 (1): 9–21. DOI:10.1517/eoed.9.1.9.32956. PMID 15155133.
Salomé N, Stemmelin J, Cohen C, Griebel G (April 2006). „Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils”. Pharmacol. Biochem. Behav. 83 (4): 533–9. DOI:10.1016/j.pbb.2006.03.013. PMID 16624395.
Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G (March 2008). „Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models”. Pharmacol. Biochem. Behav. 89 (1): 36–45. DOI:10.1016/j.pbb.2007.10.020. PMID 18045668.
Spooren W, Riemer C, Meltzer H (December 2005). „Opinion: NK3 receptor antagonists: the next generation of antipsychotics?”. Nat Rev Drug Discov 4 (12): 967–75. DOI:10.1038/nrd1905. PMID 16341062.
Chahl LA (August 2006). „Tachykinins and neuropsychiatric disorders”. Curr Drug Targets 7 (8): 993–1003. DOI:10.2174/138945006778019309. PMID 16918327. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.
Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer A (August 2006). „Tachykinins in the respiratory tract”. Curr Drug Targets 7 (8): 1005–10. DOI:10.2174/138945006778019318. PMID 16918328. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.
Improta G, Broccardo M (August 2006). „Tachykinins: role in human gastrointestinal tract physiology and pathology”. Curr Drug Targets 7 (8): 1021–9. DOI:10.2174/138945006778019354. PMID 16918330. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.
Boot JD, de Haas S, Tarasevych S, et al. (March 2007). „Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma”. Am. J. Respir. Crit. Care Med. 175 (5): 450–7. DOI:10.1164/rccm.200608-1186OC. PMID 17170385.
Navari RM (December 2007). „Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting”. Expert Opin Investig Drugs 16 (12): 1977–85. DOI:10.1517/13543784.16.12.1977. PMID 18042005.
Hickman MA, Cox SR, Mahabir S, et al. (June 2008). „Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats”. J. Vet. Pharmacol. Ther. 31 (3): 220–9. DOI:10.1111/j.1365-2885.2008.00952.x. PMID 18471143.
Quartara L, Altamura M (August 2006). „Tachykinin receptors antagonists: from research to clinic”. Curr Drug Targets 7 (8): 975–92. DOI:10.2174/138945006778019381. PMID 16918326. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.

elsevier.com

linkinghub.elsevier.com

Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C (August 1993). „Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior”. Physiol. Behav. 54 (2): 249–58. DOI:10.1016/0031-9384(93)90107-Q. PMID 7690487.

jneurosci.org

Carter MS, Krause JE (July 1990). „Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma”. J. Neurosci. 10 (7): 2203–14. PMID 1695945.

nih.gov

ncbi.nlm.nih.gov

Grace RC, Lynn AM, Cowsik SM (February 2001). „Lipid induced conformation of the tachykinin peptide Kassinin”. J. Biomol. Struct. Dyn. 18 (4): 611–21, 623–5. PMID 11245256.
Carter MS, Krause JE (July 1990). „Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma”. J. Neurosci. 10 (7): 2203–14. PMID 1695945.
Maggio JE (1988). „Tachykinins”. Annu. Rev. Neurosci. 11: 13–28. DOI:10.1146/annurev.ne.11.030188.000305. PMID 3284438.
Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ (1990). „Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms”. Faseb J. 4 (6): 1606–15. PMID 1969374.
Avanov AIa (1992). „Tachykinins and conformational aspects of their interactions with receptors”. Mol. Biol. (Mosk) 26 (1): 5–24. PMID 1324401.
Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C (August 1993). „Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior”. Physiol. Behav. 54 (2): 249–58. DOI:10.1016/0031-9384(93)90107-Q. PMID 7690487.
Online Mendelovsko nasleđivanje kod čoveka (OMIM) TAC1 -162320
Online Mendelovsko nasleđivanje kod čoveka (OMIM) TAC3 -162330
Alvaro G, Di Fabio R (September 2007). „Neurokinin 1 receptor antagonists--current prospects”. Curr Opin Drug Discov Devel 10 (5): 613–21. PMID 17786860.
Duffy RA (May 2004). „Potential therapeutic targets for neurokinin-1 receptor antagonists”. Expert Opin Emerg Drugs 9 (1): 9–21. DOI:10.1517/eoed.9.1.9.32956. PMID 15155133.
Salomé N, Stemmelin J, Cohen C, Griebel G (April 2006). „Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils”. Pharmacol. Biochem. Behav. 83 (4): 533–9. DOI:10.1016/j.pbb.2006.03.013. PMID 16624395.
Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G (March 2008). „Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models”. Pharmacol. Biochem. Behav. 89 (1): 36–45. DOI:10.1016/j.pbb.2007.10.020. PMID 18045668.
Spooren W, Riemer C, Meltzer H (December 2005). „Opinion: NK3 receptor antagonists: the next generation of antipsychotics?”. Nat Rev Drug Discov 4 (12): 967–75. DOI:10.1038/nrd1905. PMID 16341062.
Chahl LA (August 2006). „Tachykinins and neuropsychiatric disorders”. Curr Drug Targets 7 (8): 993–1003. DOI:10.2174/138945006778019309. PMID 16918327. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.
Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer A (August 2006). „Tachykinins in the respiratory tract”. Curr Drug Targets 7 (8): 1005–10. DOI:10.2174/138945006778019318. PMID 16918328. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.
Improta G, Broccardo M (August 2006). „Tachykinins: role in human gastrointestinal tract physiology and pathology”. Curr Drug Targets 7 (8): 1021–9. DOI:10.2174/138945006778019354. PMID 16918330. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.
Boot JD, de Haas S, Tarasevych S, et al. (March 2007). „Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma”. Am. J. Respir. Crit. Care Med. 175 (5): 450–7. DOI:10.1164/rccm.200608-1186OC. PMID 17170385.
Navari RM (December 2007). „Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting”. Expert Opin Investig Drugs 16 (12): 1977–85. DOI:10.1517/13543784.16.12.1977. PMID 18042005.
Hickman MA, Cox SR, Mahabir S, et al. (June 2008). „Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats”. J. Vet. Pharmacol. Ther. 31 (3): 220–9. DOI:10.1111/j.1365-2885.2008.00952.x. PMID 18471143.
Quartara L, Altamura M (August 2006). „Tachykinin receptors antagonists: from research to clinic”. Curr Drug Targets 7 (8): 975–92. DOI:10.2174/138945006778019381. PMID 16918326. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.

web.archive.org

Chahl LA (August 2006). „Tachykinins and neuropsychiatric disorders”. Curr Drug Targets 7 (8): 993–1003. DOI:10.2174/138945006778019309. PMID 16918327. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.
Groneberg DA, Harrison S, Dinh QT, Geppetti P, Fischer A (August 2006). „Tachykinins in the respiratory tract”. Curr Drug Targets 7 (8): 1005–10. DOI:10.2174/138945006778019318. PMID 16918328. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.
Improta G, Broccardo M (August 2006). „Tachykinins: role in human gastrointestinal tract physiology and pathology”. Curr Drug Targets 7 (8): 1021–9. DOI:10.2174/138945006778019354. PMID 16918330. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.
Quartara L, Altamura M (August 2006). „Tachykinin receptors antagonists: from research to clinic”. Curr Drug Targets 7 (8): 975–92. DOI:10.2174/138945006778019381. PMID 16918326. Arhivirano iz originala na datum 2009-03-28. Pristupljeno 2014-04-09.